

References

I-120

1. Momtaz P, Postow MA. Immunologic checkpoints in cancer therapy: Focus on the programmed death-1 (PD-1) receptor pathway. *Pharmgenomics Pers Med*. 2014;7:357–365.
2. Forde P, Reiss K, Zeidan A, et al. What lies within: Novel strategies in immunotherapy for non-small cell lung cancer. *Oncologist*. 2013:1203-1213.
3. Opdivo® (nivolumab) [package insert]. Bristol-Myers Squibb Company, Princeton, NJ 08543. 12/2014. Revised April 2018.
4. Keytruda® (pembrolizumab) [package insert]. Merck & Co., Inc., Whitehouse Station, NJ 08889. 09/2014. Revised November 2017.
5. Robert C, Shachter J, Long G, et al. Pembrolizumab versus ipilimumab in advanced melanoma. *The New England Journal of Medicine*. 2015;DOI:10.1056/NEJMoa1503093.
6. Johnson DB, Peng C, Sosman JA. Nivolumab in melanoma: Latest evidence and clinical potential. *Therapeutic Advances in Medical Oncology*. 2015;7(2):97–106.
7. Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma. *The New England Journal of Medicine*. 2015;372(4):311-319.
8. Antonia SJ, Bendell JC, Taylor MH, et al. Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers. *J Clin Oncol* 33, 2015 (suppl; abstr 7503).
9. Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. *N Engl J Med* 2015;373:1803-13.
10. Pembrolizumab. DrugPoints Summary. Micromedex 2.0. Truven Health Analytics, Inc. Greenwood Village, CO. Accessed 10/11/2016.
11. Sharma P, Retz M, Siefker-Radtke A, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): A multicentre, single-arm, phase 2 trial. *Lancet Oncol*. 2017.
12. MICROMEDEX®SOLUTIONS Compendia. 2017. Atezolizumab.
13. MICROMEDEX®SOLUTIONS Compendia. 2017. Avelumab.
14. MICROMEDEX®SOLUTIONS Compendia. 2017. Durvalumab.
15. MICROMEDEX®SOLUTIONS Compendia. 2017. Nivolumab
16. MICROMEDEX®SOLUTIONS Compendia. 2017. Pembrolizumab.
17. Bavencio® (avelumab) [package insert]. EMD Serono, Inc. Rockland, MA. 03/2017. Revised October 2017.
18. Gupta S, Gill D, Poole A, et al. Systemic immunotherapy for urothelial cancer: Current trends and future directions. *Cancers (Basel)*. 2017; 9(2): 15.
19. Imfinzi™ (durvalumab) [package insert]. AstraZeneca Pharmaceuticals LP, Wilmington, DE. February 2018.

20. Villaruz L, Socinski M. The clinical utility of PD-L1 testing in selecting non-small cell lung cancer patients for PD1/PD-L1 directed therapy. *Clin Pharmacol Ther.* 2016; 100(3): 212–214.
21. American Cancer Society (ACS). Key Statistics for Bladder Cancer. January 5, 2017.
22. Tecentriq® (atezolizumab) [package insert]. Genentech, Inc., South San Francisco, CA 94080. October 2016. Revised March 2018.
23. National Comprehensive Cancer Network (NCCN). NCCN Atezolizumab. Version 3.2018.
24. National Comprehensive Cancer Network (NCCN). NCCN Avelumab. Version 1.2018.
25. National Comprehensive Cancer Network (NCCN). NCCN Durvalumab. Version 3.2018.
26. National Comprehensive Cancer Network (NCCN). NCCN Nivolumab. Version 1.2018.
27. National Comprehensive Cancer Network (NCCN). NCCN Pembrolizumab. Version 1.2018.
28. Clinical Pharmacology Compendia. 2018 Tampa FL: Gold Standard, Inc. Atezolizumab.
29. Clinical Pharmacology Compendia. 2018 Tampa FL: Gold Standard, Inc. Avelumab.
30. Clinical Pharmacology Compendia. 2018 Tampa FL: Gold Standard, Inc. Durvalumab.
31. Clinical Pharmacology Compendia. 2018 Tampa FL: Gold Standard, Inc. Nivolumab.
32. Clinical Pharmacology Compendia. 2018 Tampa FL: Gold Standard, Inc. Pembrolizumab.
33. Tomasini P, Greillier L, Boyer A, Jeanson A, & Barlesi F. Durvalumab After Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer. *J Thorac Dis.* 2018; 10(9):S1032-S1036.
34. Johnson B & Eng C. The Promise of Immunotherapy in Anal Squamous Cell Carcinoma: A Novel Approach for an Orphan Disease. *Clin Adv Hematol Oncol.* December 2017;15(12):968-978.
35. Kudo M. Immune Checkpoint Inhibition in hepatocellular Carcinoma: Basics and Ongoing Clinical Trials. *Oncology.* 2017;92(suppl 1):50-62.
36. Chan I, Bhatia S, Kaufman H, & Lipson E. Immunotherapy for Merkel Cell Carcinoma: a Turning Point in Patient Care. *J Immunother Cancer Res.* 2018; 6:23.
37. Algazi A, Tsai K, Shoushtari A, et al. Clinical Outcomes in Metastatic Uveal Melanoma Treated with PD-1 and PD-L1 Antibodies. *Cancer.* 2016; 122(21):3344-3353.
38. Le D, Uram J, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. *N Engl J Med.* 2015; 372:2509-2520.
39. Kwong Y, Chan T, Tan D, et al. PD1 Blockade with Pembrolizumab is Highly Effective in Relapsed or Refractory NK/T-cll Lymphoma Failing L-Asparaginase. *Blood.* 2017; 129:2437-2442.
40. Doi T, Piha-Paul S, Jalal S, et al. Safety and Antitumor Activity of the Anti-Programmed Death-1 Antibody Pembrolizumab in Patients with Advanced Esophageal Carcinoma. *J Clin Onco.* 2018;

36:61-67.